tiprankstipranks
Trending News
More News >
Cynata Therapeutics Limited (AU:CYP)
:CYP
Australian Market

Cynata Therapeutics Limited (CYP) Drug Pipeline

Compare
8 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Corticosteroids, Cyp-001: Cymerus Induced Pluripotent Stem Cell (Ipsc)-Derived Mesenchymal Stem Cells (Mscs)
Graft Versus Host Disease, Acute
Phase II
Recruiting
A Study of CYP-001 in Combination with Corticosteroids in Adults with High-risk AGvHD
Nov 29, 2022
Cyp-006Tk
Diabetic Foot Ulcer, Cutaneous Ulcer
Phase I
Completed
Safety, Tolerability and Efficacy of CYP-006TK in Adults with Diabetic Foot Ulcers
Oct 18, 2021
Cyp-001
COVID19, Acute Respiratory Distress Syndrome
Phase I
Completed
The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause
Aug 25, 2020
Mesenchymoangioblast-Derived Mesenchymal Stem Cells
Graft Vs Host Disease
Phase I
Completed
A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease
Oct 03, 2016

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Cynata Therapeutics Limited (CYP) have in its pipeline
      CYP is currently developing the following drugs: Corticosteroids, Cyp-001: Cymerus Induced Pluripotent Stem Cell (Ipsc)-Derived Mesenchymal Stem Cells (Mscs), Cyp-006Tk, Cyp-001. These drug candidates are in various stages of clinical development as the company works toward FDA approval.